Clinical experience with biphasic insulin aspart in people with type 2 diabetes: Results from the Libya cohort of the A 1 chieve study

• Published in: Indian journal of endocrinology and metabolism Vol. 17; no. 8; pp. 435 - 436
• Main Authors: Hajjaji, IssamM, Sherif, Ibrahim, Elazrag, Aisha, Jaber, Suhair, Chakkarwar, PrafulN, Eltabal, Salem
• Format: Journal Article
• Language: English
• Published: Medknow Publications and Media Pvt. Ltd 01-11-2013; Wolters Kluwer Medknow Publications
• Subjects: A 1 chieve study; biphasic insulin aspart; Diagnosis; Drug therapy; Health aspects; Insulin; Libya; Type 2 diabetes; type 2 diabetes mellitus; Libya
• ISSN: 2230-8210; 2230-9500
• DOI: 10.4103/2230-8210.122062

Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. Materials and Methods: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled in biphasic insulin aspart sub group from Libya. Results: A total of 179 patients were enrolled in the biphasic insulin aspart subgroup. All the patients were prior insulin users. At baseline glycaemic control was poor (mean HbA 1 c: 9.3%). After 24 weeks of treatment there was an improvement in HbA 1 c (−0.9%). Hypoglycaemic events reduced from 7.2 events/patient-year to 3.7 events/patient-year in 24 weeks. SADRs did not occur in any of the study patients. Conclusion: Starting or switching to biphasic insulin aspart was associated with improvement in glycaemic control with a low rate of hypoglycaemia.